Diligence memo · auto-generated · as of July 2, 2026
Paringenix Inc
Paringenix Inc looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Paringenix Inc operates in Pharmaceuticals, based in WESTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Paringenix Inc has raised $11M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.4M on 2010-08-03.
Most recent recorded round closed around 2013-02-08.
Valuation (modeled)modeled
Provath models Paringenix Inc at approximately $101M (range $3.7M–$551M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.52× the median modeled value of Series A Pharmaceuticals companies in 2013–2015 (64 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 13.4 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 3.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 55% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 55% of those peers.
Closest niche peers: Aquinox Pharmaceuticals (Usa) Inc, Neurovia, Inc., Romark Global Pharma, LLC, Access Pharmaceuticals Inc, Minnesota Medical Solutions LLC.
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.